

<b>NCT ID</b>	NCT06310564
<b>Title</b>	Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2024-03-15
<b>Location</b>	Italy
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06026774
<b>Title</b>	Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-07
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06034860
<b>Title</b>	Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-13
<b>Location</b>	California, United States Indiana, United States Missouri, United States New York, United States Virginia, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	MT-8421, Nivolumab, Opdivo
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT06039202
<b>Title</b>	Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-09-15
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	CA102N, TAS-102
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06039384

<b>Title</b>	A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-15
<b>Location</b>	California, United States Colorado, United States Michigan, United States Texas, United States Virginia, United States Italy Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Adagrasib, INCB099280
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06047015
<b>Title</b>	Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-21
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06043713
<b>Title</b>	Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-21
<b>Location</b>	Washington, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bendamustine, Cyclophosphamide, Fludarabine
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06055439
<b>Title</b>	A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-09-26
<b>Location</b>	Georgia, United States Illinois, United States Pennsylvania, United States Tennessee, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting

<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06060704
<b>Title</b>	Envafohimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-09-29
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Bevacizumab, Envafohimab, Trifluridine/Tipiracil, Avastin, Lonsurf
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06065371
<b>Title</b>	Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-10-03
<b>Location</b>	Michigan, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	capecitabine, Sacituzumab govetican
<b>Tags</b>	MSS/ MMRp